419 related articles for article (PubMed ID: 33890574)
21. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
[TBL] [Abstract][Full Text] [Related]
22. MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.
Branigan TB; Kozono D; Schade AE; Deraska P; Rivas HG; Sambel L; Reavis HD; Shapiro GI; D'Andrea AD; DeCaprio JA
Cell Rep; 2021 Mar; 34(9):108808. PubMed ID: 33657372
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
Bu H; Li Y; Jin C; Yu H; Wang X; Chen J; Wang Y; Ma Y; Zhang Y; Kong B
Int J Oncol; 2020 Mar; 56(3):685-696. PubMed ID: 31922238
[TBL] [Abstract][Full Text] [Related]
24. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
25. OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer.
Wang Y; Zhou X; Xu M; Weng W; Zhang Q; Yang Y; Wei P; Du X
Oncotarget; 2016 Jun; 7(24):36681-36697. PubMed ID: 27167337
[TBL] [Abstract][Full Text] [Related]
26. PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway.
Biegała Ł; Gajek A; Marczak A; Rogalska A
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188633. PubMed ID: 34619333
[TBL] [Abstract][Full Text] [Related]
27. Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.
Nakagawa-Saito Y; Mitobe Y; Suzuki S; Togashi K; Sugai A; Kitanaka C; Okada M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445993
[TBL] [Abstract][Full Text] [Related]
28. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
Gupta N; Huang TT; Horibata S; Lee JM
Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
[TBL] [Abstract][Full Text] [Related]
29. Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition.
Fang P; Madden JA; Neums L; Moulder RK; Forrest ML; Chien J
Mol Cancer Res; 2018 Jun; 16(6):961-973. PubMed ID: 29545475
[TBL] [Abstract][Full Text] [Related]
30. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
31. Targeting DNA repair: the genome as a potential biomarker.
Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
[TBL] [Abstract][Full Text] [Related]
32. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
[TBL] [Abstract][Full Text] [Related]
33. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.
Wang D; Hu G; Du Y; Zhang C; Lu Q; Lv N; Luo S
J Exp Clin Cancer Res; 2017 Feb; 36(1):23. PubMed ID: 28148279
[TBL] [Abstract][Full Text] [Related]
34. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
Liu K; Graves JD; Lin FT; Lin WC
J Biol Chem; 2021; 296():100382. PubMed ID: 33556369
[TBL] [Abstract][Full Text] [Related]
36. The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells.
Zhu X; Xue L; Yao Y; Wang K; Tan C; Zhuang M; Zhou F; Zhu L
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):914-920. PubMed ID: 30060118
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of FoxM1 sensitizes nasopharyngeal carcinoma cells to cisplatin via inhibition of MRN-ATM-mediated DNA repair.
Li D; Ye L; Lei Y; Wan J; Chen H
BMB Rep; 2019 Mar; 52(3):208-213. PubMed ID: 30638177
[TBL] [Abstract][Full Text] [Related]
38. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
40. FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7.
Zhang Z; Tu K; Liu F; Liang M; Yu K; Wang Y; Luo Y; Yang B; Qin Y; He D; Jiang G; Huang O; Zou Y
Gene; 2020 Oct; 757():144947. PubMed ID: 32659254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]